Core Viewpoint - Recently, the company reported a decline in revenue and incurred losses for the first three quarters of 2025, indicating challenges in its financial performance [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 581 million, a year-on-year decrease of 4.1% [1] - The net profit attributable to the parent company was a loss of 45.92 million [1] - In the third quarter, the operating revenue was 204 million, reflecting a year-on-year decline of 8.9% [1] - The net profit attributable to the parent company for the third quarter was a loss of 14.54 million [1] Regulatory Approvals - During the reporting period, the company received approval from the National Medical Products Administration for the injection of Mycophenolate Mofetil (specification: 0.5g) and obtained drug registration certificates for Nicorandil tablets (specification: 5mg) and Ketorolac Tromethamine injection (specification: 1ml: 30mg) [1] Shareholding Changes - On September 26, 2025, the company was notified by its controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as "Zhongheng Group"), about a capital increase agreement and share transfer agreement signed by its indirect controlling shareholder, Guangxi Investment Group Co., Ltd. (hereinafter referred to as "Guangxi Investment Group") [1] - Guangxi Investment Group plans to increase capital in Guangxi Investment Group Financial Holdings Co., Ltd. (hereinafter referred to as "Guangxi Financial Holdings") by transferring 859,343,587 shares of Zhongheng Group [1] - After the completion of this transaction, Guangxi Financial Holdings will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the Guangxi State-owned Assets Supervision and Administration Commission will continue to be the actual controller of the company [1]

尼可地尔片用于心绞痛的治疗。最早由日本中外制药有限公司开发，1983年在日本上市销售，2006年批 准进入中国市场，商品名为喜格迈（Sigmart）。 根据摩熵医药数据，2022年—2024年，尼可地尔片在 中国医院全终端市场销售额由6.76亿元攀升至8.73亿元，该产品的获批将有力补充公司心血管产品线， 提升市场覆盖能力。 酮咯酸氨丁三醇注射液适用于中度至重度急性术后疼痛的短期治疗。该药物由瑞士的罗氏（Roche）公 司研发，于1989年11月在美国上市。该药于2005年在中国获批上市，由山东新时代药业有限公司（鲁南 制药集团旗下）推出，用于成人术后中度至重度急性疼痛的短期治疗。根据摩熵医药数据，酮咯酸氨丁 三醇注射液2022年—2024年在中国医院（全终端）市场销售额分别为26.43亿元、18.92亿元、8.98亿 元。 莱美药业表示，未来，公司将持续聚焦优势细分领域，保持新品持续引进，加快对已引入新品的上市转 换，加大自主创新力度，积极迎接医药行业的机遇并应对挑战，推动公司健康持续发展。 （文章来源：证券时报网） 10月21日晚间，莱美药业(300006)发布三季报，前三季度，公司报告期实现营业收入5. ...

Core Viewpoint - The announcement highlights that Guangxi Wuzhou Zhongheng Group Co., Ltd.'s subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received drug registration certificates for two medications, Nicorandil Tablets and Ketorolac Tromethamine Injection, which will enhance the company's product line and market presence [1][3]. Group 1: Drug Registration Details - Chongqing Laimei Pharmaceutical has obtained registration for Nicorandil Tablets (5mg) and Ketorolac Tromethamine Injection (1ml:30mg) from the National Medical Products Administration [1][5]. - Nicorandil Tablets are indicated for the treatment of angina pectoris, originally developed by Daiichi Sankyo Co., Ltd. and launched in Japan in 1983, with sales in China starting in 2006 [1][2]. - Sales projections for Nicorandil Tablets in Chinese hospitals from 2022 to 2024 are estimated at CNY 676 million, CNY 789 million, and CNY 873 million, respectively [1][2]. Group 2: Market and Financial Impact - Ketorolac Tromethamine Injection is used for the short-term treatment of moderate to severe postoperative pain, developed by Roche and approved in China in 2005 [2]. - Sales projections for Ketorolac Tromethamine Injection in Chinese hospitals from 2022 to 2024 are estimated at CNY 2.643 billion, CNY 1.892 billion, and CNY 898 million, respectively [2]. - The total R&D investment for Nicorandil Tablets and Ketorolac Tromethamine Injection by Laimei Pharmaceutical is CNY 5.3879 million and CNY 4.7431 million, respectively [2].

Core Insights - Zhongheng Group announced the approval of two drugs by the National Medical Products Administration, indicating a positive development for the company's product portfolio [2] Drug Approval Details - The approved drugs include Nicardipine Tablets (specification: 5mg) and Ketorolac Tromethamine Injection (specification: 1ml: 30mg) [2]

每经AI快讯，中恒集团（SH 600252，收盘价：2.91元）9月17日晚间发布公告称，近日，广西梧州中恒 集团股份有限公司的控股子公司重庆莱美药业股份有限公司收到国家药品监督管理局核准签发的尼可地 尔片、酮咯酸氨丁三醇注射液两个药品的《药品注册证书》。 2024年1至12月份，中恒集团的营业收入构成为：医药制造业占比76.26%，其他业务占比13.84%，食品 占比9.9%。 截至发稿，中恒集团市值为93亿元。 每经头条（nbdtoutiao）——海拔4306米现"秦始皇密令"，获官方"身份认定"！古文字学家刘钊：秦人 寻仙采药足迹确至青藏高原 （记者 张喜威） ...

中恒集团9月17日公告，公司控股子公司重庆莱美药业股份有限公司收到国家药品监督管理局核准签发 的尼可地尔片（规格:5mg）、酮咯酸氨丁三醇注射液（规格:1ml:30mg）两个药品的《药品注册证 书》。尼可地尔片用于心绞痛的治疗。酮咯酸氨丁三醇注射液适用于中度至重度急性术后疼痛的短期治 疗。 ...

Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, has received approval from the National Medical Products Administration for two drugs, which will enhance the company's product line [1] Group 1: Drug Approvals - Laimei Pharmaceutical has obtained drug registration certificates for Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml:30mg) [1] - Nicorandil tablets are indicated for the treatment of angina pectoris, while Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe postoperative pain [1] Group 2: R&D Investment - The total R&D investment for Nicorandil tablets was approximately RMB 5.39 million, and for Ketorolac Tromethamine injection, it was around RMB 4.74 million [1] - The approval of these drugs is expected to further enrich the company's product offerings [1]

格隆汇9月17日丨中恒集团(600252.SH)公布，公司的控股子公司重庆莱美药业股份有限公司（以下简 称"莱美药业"）收到国家药品监督管理局核准签发的尼可地尔片（规格：5mg）、酮咯酸氨丁三醇注射 液（规格：1ml:30mg）两个药品的《药品注册证书》，本次控股子公司莱美药业取得尼可地尔片（规 格：5mg）、酮咯酸氨丁三醇注射液（规格：1ml:30mg）两个药品的《药品注册证书》，有利于进一步 丰富公司产品线。 ...

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received drug registration certificates for two products, which will enhance the company's product line [1] Group 1 - The approved drugs are Nicardipine Tablets (5mg) and Ketorolac Tromethamine Injection (1ml:30mg) [1] - The approval from the National Medical Products Administration is a significant milestone for the company [1] - The addition of these products is expected to contribute positively to the company's growth and market presence [1]

Company Overview - Recently, Laimei Pharmaceutical (SZ 300006, closing price: 4.58 yuan) announced the approval of two drug registration certificates by the National Medical Products Administration for Nicorandil tablets and Ketorolac Tromethamine injection [1] Financial Performance - For the year 2024, Laimei Pharmaceutical's revenue composition is as follows: 84.09% from pharmaceutical manufacturing, 13.06% from pharmaceutical distribution, 1.64% from other businesses, and 1.21% from service income [1] Market Position - As of the report, Laimei Pharmaceutical has a market capitalization of 4.8 billion yuan [1]